Beyond Air rises on positive data for inhaled nitric oxide to treat COVID-19

Beyond Air

24/10/2022 17:18

** Shares of medical device maker Beyond Air Inc  XAIR.O 
rise 4.9% to $7.16
    ** Co reports positive data for inhaled nitric oxide (NO) 
from a pilot study in treating COVID-19 and other
community-acquired viral pneumonia (VCAP) with its device
LungFit Pro  urn:newsml:reuters.com:*:nGNX9LHrxv
    ** The study testing 40 VCAP patients showed improved
efficacy on multiple parameters in the inhaled NO group vs
patients receiving standard supportive treatment - XAIR
    ** XAIR says duration of oxygen support was significantly
shorter for subjects treated with inhaled NO
    ** Also says safety data from the study show that inhaled NO
treatment was well tolerated overall with no treatment related
adverse events 
    ** Including session's gain, stock down 24.14% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))